FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2178081024> ?p ?o ?g. }

• W2178081024 endingPage "573" @default.
• W2178081024 startingPage "566" @default.
• W2178081024 abstract "Strategies to prevent postnatal mother-to-child transmission of HIV-1 in Africa, including infant prophylaxis, have never been assessed past 6 months of breastfeeding, despite breastfeeding being recommended up to 12 months after birth. We aimed to compare the efficacy and safety of infant prophylaxis with the two drug regimens (lamivudine or lopinavir-ritonavir) to prevent postnatal HIV-1 transmission up to 50 weeks of breastfeeding.We did a randomised controlled trial in four sites in Burkina Faso, South Africa, Uganda, and Zambia in children born to HIV-1-infected mothers not eligible for antiretroviral therapy (CD4 count >350 cells per μL). An independent researcher electronically generated a randomisation schedule; we then used sequentially numbered envelopes to randomly assign (1:1) HIV-1-uninfected breastfed infants aged 7 days to either lopinavir-ritonavir or lamivudine (paediatric liquid formulations, twice a day) up to 1 week after complete cessation of breastfeeding or at the final visit at week 50. We stratified the randomisation by country and used permuted blocks of four and six. We used a study label on drug bottles to mask participants, study physicians, and assessors to the treatment allocation. The primary outcome was infant HIV-1 infection between age 7 days and 50 weeks, diagnosed every 3 months with HIV-1 DNA PCR, in the modified intention-to-treat population (all who attended at least one follow-up visit). This trial is registered with ClinicalTrials.gov, number NCT00640263.Between Nov 16, 2009, and May 7, 2012, we enrolled and randomised 1273 infants and analysed 1236; 615 assigned to lopinavir-ritonavir or 621 assigned to lamivudine. 17 HIV-1 infections were diagnosed in the study period (eight in the lopinavir-ritonavir group and nine in the lamivudine group), resulting in cumulative HIV-1 infection of 1.4% (95% CI 0.4-2.5) and 1.5% (0.7-2.5), respectively. Infection rates did not differ between the two drug regimens (hazard ratio [HR] of lopinavir-ritonavir versus lamivudine of 0.90, 95% CI 0.35-2.34; p=0.83). Clinical and biological severe adverse events did not differ between groups; 251 (51%) infants had a grade 3-4 event in the lopinavir-ritonavir group compared with 246 (50%) in the lamivudine group.Infant HIV-1 prophylaxis with lopinavir-ritonavir was not superior to lamivudine and both drugs led to very low rates of HIV-1 postnatal transmission for up to 50 weeks of breastfeeding. Infant pre-exposure prophylaxis should be extended until the end of HIV-1 exposure and mothers should be informed about the persistent risk of transmission throughout breastfeeding.INSERM/National Agency for Research on AIDS and Viral Hepatitis (including funds from the Total Foundation), European Developing Countries Clinical Trials Partnership, Research Council of Norway." @default.
• W2178081024 created "2016-06-24" @default.
• W2178081024 creator A5001124285 @default.
• W2178081024 creator A5001181972 @default.
• W2178081024 creator A5003944606 @default.
• W2178081024 creator A5005072339 @default.
• W2178081024 creator A5006020664 @default.
• W2178081024 creator A5006556877 @default.
• W2178081024 creator A5009524078 @default.
• W2178081024 creator A5010458827 @default.
• W2178081024 creator A5013411579 @default.
• W2178081024 creator A5013947538 @default.
• W2178081024 creator A5014450217 @default.
• W2178081024 creator A5015062515 @default.
• W2178081024 creator A5016638923 @default.
• W2178081024 creator A5019384342 @default.
• W2178081024 creator A5022334430 @default.
• W2178081024 creator A5026202001 @default.
• W2178081024 creator A5027073078 @default.
• W2178081024 creator A5027807881 @default.
• W2178081024 creator A5027888105 @default.
• W2178081024 creator A5028177604 @default.
• W2178081024 creator A5028449341 @default.
• W2178081024 creator A5030111450 @default.
• W2178081024 creator A5031395597 @default.
• W2178081024 creator A5033196789 @default.
• W2178081024 creator A5036756556 @default.
• W2178081024 creator A5036850263 @default.
• W2178081024 creator A5037696502 @default.
• W2178081024 creator A5039531201 @default.
• W2178081024 creator A5039928708 @default.
• W2178081024 creator A5040087395 @default.
• W2178081024 creator A5041516879 @default.
• W2178081024 creator A5042239448 @default.
• W2178081024 creator A5044578316 @default.
• W2178081024 creator A5045086794 @default.
• W2178081024 creator A5045788813 @default.
• W2178081024 creator A5048987797 @default.
• W2178081024 creator A5049611673 @default.
• W2178081024 creator A5049647036 @default.
• W2178081024 creator A5049803987 @default.
• W2178081024 creator A5050562298 @default.
• W2178081024 creator A5051621566 @default.
• W2178081024 creator A5052608832 @default.
• W2178081024 creator A5052612659 @default.
• W2178081024 creator A5053289001 @default.
• W2178081024 creator A5055853267 @default.
• W2178081024 creator A5057792383 @default.
• W2178081024 creator A5057946567 @default.
• W2178081024 creator A5061375133 @default.
• W2178081024 creator A5063014330 @default.
• W2178081024 creator A5063257130 @default.
• W2178081024 creator A5064382030 @default.
• W2178081024 creator A5065248098 @default.
• W2178081024 creator A5065679272 @default.
• W2178081024 creator A5066702439 @default.
• W2178081024 creator A5066733759 @default.
• W2178081024 creator A5066889157 @default.
• W2178081024 creator A5067045991 @default.
• W2178081024 creator A5067055005 @default.
• W2178081024 creator A5068950984 @default.
• W2178081024 creator A5069692988 @default.
• W2178081024 creator A5072140170 @default.
• W2178081024 creator A5072392021 @default.
• W2178081024 creator A5074387253 @default.
• W2178081024 creator A5075656106 @default.
• W2178081024 creator A5075916576 @default.
• W2178081024 creator A5076444863 @default.
• W2178081024 creator A5078125231 @default.
• W2178081024 creator A5080132218 @default.
• W2178081024 creator A5080498436 @default.
• W2178081024 creator A5081431218 @default.
• W2178081024 creator A5082482866 @default.
• W2178081024 creator A5083763747 @default.
• W2178081024 creator A5083946071 @default.
• W2178081024 creator A5084499231 @default.
• W2178081024 creator A5084638245 @default.
• W2178081024 creator A5086416739 @default.
• W2178081024 creator A5086534665 @default.
• W2178081024 creator A5090087378 @default.
• W2178081024 date "2016-02-01" @default.
• W2178081024 modified "2023-10-18" @default.
• W2178081024 title "Extended pre-exposure prophylaxis with lopinavir–ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial" @default.
• W2178081024 cites W1972528060 @default.
• W2178081024 cites W1984764981 @default.
• W2178081024 cites W1999871051 @default.
• W2178081024 cites W2009367857 @default.
• W2178081024 cites W2025471918 @default.
• W2178081024 cites W2038183880 @default.
• W2178081024 cites W2039836366 @default.
• W2178081024 cites W2040830489 @default.
• W2178081024 cites W2042296356 @default.
• W2178081024 cites W2056053069 @default.
• W2178081024 cites W2072612814 @default.
• W2178081024 cites W2074960015 @default.
• W2178081024 cites W2076646492 @default.
• W2178081024 cites W2110450357 @default.
• W2178081024 cites W2116914456 @default.

• next